U.S. FTC requires Amneal and Impax to divest rights to 10 generic drugs
The U.S. Federal Trade Commission said on Friday it would require Impax Laboratories Inc and privately held Amneal Pharmaceuticals LLC to divest rights to 10 generic medications as a condition of their merger.
from Biotech News
0 Comments